Tari King, MD, and Elizabeth Ann Mittendorf, MD, PhD, co-directors of the Ductal Carcinoma in Situ (DCIS) Program at Dana-Farber Brigham Cancer Center, review treatment options for patients diagnosed with DCIS.
DCIS is the earliest form of breast cancer where the abnormal cells are confined within the milk duct of the breast. DCIS is sometimes referred to as stage 0 cancer, non-invasive breast cancer, or pre-cancer. Treatment options may include surgery, radiation therapy, and medication (hormone) therapy. It is generally safe for patients to take the time they need to evaluate all of their options and collaborate with their care team to decide what treatment is right for them.
To learn more about the DCIS Program, visit www.dana-farber.org/ductal-carcinoma-in-situ-program.
